Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-4/RTOG-3515 durvalumab with SBRT in unresected stage I/II node-negative NSCLC
jRCT2080224593Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing SoC SBRT + durvalumab, SoC SBRT + placebo and SoC SBRT + osimertinib (3 arms). Started Mar 2019; status: completed.
02
Drugs
durvalumabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224593.